| Document |
Document Title |
|
WO/2024/006187A1 |
Provided herein are methods of treating cancer comprising a KRAS G12C mutation in a patient comprising (a) administering to the patient a therapeutically effective amount of sotorasib for 14 to 48 days ("an induction period''), and (b) a...
|
|
WO/2024/003787A1 |
The present invention provides a composition for preventing or treating a neurodegenerative disease containing a phosphodiesterase-5 (PDE-5) inhibitor and an anti-diabetic therapeutic including sodium-glucose cotransporter 2 (SGLT2) inhi...
|
|
WO/2024/004869A1 |
The present invention provides a peptide that can be utilized in active targeting DDS. Provided according to an embodiment of the present invention are: a peptide that has a hydrophobic region and a hydrophilic region lower in hydrophobi...
|
|
WO/2024/001470A1 |
The present invention provides an antibody targeting B7-H3, as well as a multispecific antibody, a chimeric polypeptide, an antibody conjugate, a pharmaceutical composition and a kit comprising the same, and a use thereof in the diagnosi...
|
|
WO/2024/003078A1 |
The present invention relates to a preservative-free ophthalmic composition comprising a prostaglandin analogue for use in the reduction of elevated intraocular pressure during a treatment period of at least 90 days. The composition rema...
|
|
WO/2024/000725A1 |
The present invention relates to a cancer cell-specific T cell vaccine and a method for activating cancer cell-specific T cells. T cells in peripheral blood, peripheral immune organs, or tumor-infiltrating lymphocytes are co-incubated wi...
|
|
WO/2024/003784A1 |
The present invention provides a composition for preventing or treating a neurodegenerative disease containing a phosphodiesterase 5 inhibitor (PDE5 inhibitor) and an N- methyl-D-aspartate-receptor(NMDA-receptor) antagonist and a method ...
|
|
WO/2024/006460A1 |
Biomarkers and machine learning techniques to identify biomarkers are disclosed herein. In one particular implementation, the present disclosure relates to the identification of biomarkers to be used in the detection and diagnosis of LD....
|
|
WO/2024/005019A1 |
Provided is an agent for improving cognitive function which comprises an agonist with respect to peroxisome proliferator-activated receptor alpha (PPARα). Also provided is a pharmaceutical composition which is for treating or preventing...
|
|
WO/2024/003042A1 |
The present invention relates to a composition comprising the combination of at least the following three components one or more sesquiterpene alcohol compound; one or more polymyxin compound or a derivative thereof; and one or more anti...
|
|
WO/2024/002320A1 |
The present invention provides an interfering RNA for inhibiting B7-H3 expression, use thereof, and a method for preparing cells with reduced B7-H3 expression. The interfering RNA is siRNA, a target sequence of which comprises nucleotide...
|
|
WO/2024/006901A1 |
Provided are methods for the treatment of solid tumors, including glioblastoma multiforme (GBM). For instance, provided are diffusion enhancing compounds and their use in the treatment of solid tumors in conjunction with certain imaging ...
|
|
WO/2024/003380A1 |
The present invention relates to vascular endothelial growth factor receptors (VEGFRs) inhibitors, in particular VEGFR-1 inhibitors, for use in promoting myelination and/or neuroprotection in a subject. The present invention also relates...
|
|
WO/2024/005157A1 |
The purpose of the present invention is to provide: a novel adipocyte activator; and a use thereof. The present invention provides an adipocyte activator containing SerpinA1, a SerpinA1 expression promoter, or a SerpinA1 agonist, wherein...
|
|
WO/2024/005468A1 |
The present invention relates to a composition for preventing or treating a brain tumor in a high- glucose environment, comprising a microorganism and an immune checkpoint inhibitor as active ingredients. The composition of the present i...
|
|
WO/2024/004656A1 |
Provided is a pharmaceutical composition that is a composition for treating an immune-related adverse event (irAE) in a subject who has undergone a cancer immunotherapy, the pharmaceutical composition containing anthracycline.
|
|
WO/2024/003788A1 |
A method of treating acute respiratory distress syndrome (ARDS) in a subject by applying an alternating electric field (AEF) to a region of the subject's torso. The ARDS may be caused by sepsis, viral infection, bacterial infection, near...
|
|
WO/2024/003587A1 |
The invention relates to a topical, preferably transdermal preparation and patch, which can deliver its active ingredient content into the skin with near zero-order kinetics, as well as a method for their production. The active ingredien...
|
|
WO/2024/005132A1 |
The present invention provides a novel therapeutic or prophylactic agent for psoriasis. This therapeutic or prophylactic agent for psoriasis comprises a serotonin-4 receptor agonist.
|
|
WO/2024/006550A1 |
Compositions and methods for treating alopecia, particularly chemotherapy-induced alopecia, using oxidizers or oxidants, pro-oxidant compounds, or activators of P53. Compositions comprising organic peroxides such as, cumene hydroperoxide...
|
|
WO/2024/005634A1 |
The disclosure provides methods and devices for the treating or preventing a benign uterine disorder in a female mammalian subject. The methods comprise administering a non-steroidal angiogenesis inhibitor. Such methods and devices are p...
|
|
WO/2022/258838A9 |
The present invention relates to a composition for use in a method of treating cancer, the composition comprising an effective amount of at least one saponin agent, preferably ginsenoside, and an effective amount of at least one anthelmi...
|
|
WO/2023/249924A1 |
Methods of treating sleep apnea and snoring comprising administering a combination of a cannabinoid and a carbonic anhydrase inhibitor (CAI), and optionally a muscarinic receptor antagonist (MRA), are described herein. Pharmaceutical com...
|
|
WO/2023/249888A1 |
A composition that includes a micro-RNA mimic containing one or more cytosine nucleosides in which at least one cytosine nucleoside is replaced by cytosine arabinoside. Also provided is a method for killing a cancer cell by contacting it...
|
|
WO/2023/246827A1 |
The present invention relates to the technical field of biological medicines, and particularly, to a micromolecular drug-oligonucleotide conjugate and use thereof. The present invention solves the problems of poor water solubility and di...
|
|
WO/2023/249288A1 |
The present invention relates to a novel cinnamamide derivative and a use thereof in preventing or treating cancer.
|
|
WO/2023/250063A1 |
A method of treating a patient with intestinal radiation injury is disclosed. The method includes administering an effective amount of a geranylgeranyl transferase inhibitor to a patient with intestinal radiation injury. In one aspect, t...
|
|
WO/2023/250111A1 |
The present disclosure relates to therapeutic agents and combinations thereof (e.g., pharmaceutical compositions) for the treatment of a viral infection in a subject, tissue or cell.
|
|
WO/2023/246680A1 |
Provided herein are compositions (e.g., pharmaceutical compositions) of coagulation factor X activator (FX activator, e.g., RVV-X) comprising sucrose, histidine, polysorbate 20, and mannitol, and uses of FX activators (e.g., RVV-X) or co...
|
|
WO/2023/248744A1 |
Provided is a treatment method that provides a better response rate and/or life-extending effectiveness in nonhuman mammals with cancer. Provided are: a method for treating cancer in non-human mammals, the method comprising starting tr...
|
|
WO/2023/247769A1 |
This disclosure relates to compositions and methods for treating AXL-related diseases, such as cancer, in a subject. In particular, the present disclosure relates to novel dosage regimens for the treatment of AXL-related diseases, such a...
|
|
WO/2023/250110A1 |
The present disclosure relates to therapeutic agents and combinations thereof (e.g., pharmaceutical compositions) for the treatment of a viral infection in a subject, tissue or cell.
|
|
WO/2023/248206A1 |
The present invention provides a composition for preventing or treating a neurodegenerative disease containing a phosphodiesterase 5 inhibitor (PDE5 inhibitors) and an acetylcholinesterase inhibitor (AChEI) and a method using thereof, we...
|
|
WO/2023/246847A1 |
Provided are a drug for reducing a B2M level in a human brain, a drug for reducing a level of an amyloid precursor protein in the human brain, a drug for inhibiting the binding of GluN1 and B2M in the human brain, or a drug for repairing...
|
|
WO/2023/249714A1 |
The present disclosure relates generally to methods for determining whether a cancer patient will benefit from treatment with a DNA methyltransferase 1 (DNMT1) inhibitor. These methods are based on screening a cancer patient for mutation...
|
|
WO/2023/246464A1 |
The present invention provides use of a cryptotanshinone substance (such as cryptotanshinone) in the preparation of a sensitizing drug for chemotherapy of malignant tumors with high NQO1 expression, and use of a combination of the crypto...
|
|
WO/2023/245847A1 |
Disclosed is use of a boric acid small molecule compound in the preparation of drugs for enhancing the curative effect of an immune checkpoint inhibitor and treating leukemia. The boric acid small molecule compound can enhance the curati...
|
|
WO/2023/245335A1 |
Provided are the compositions (e.g., pharmaceutical compositions) of coagulation factor X activator (FX activator, e.g., RVV-X) comprising sucrose, histidine, polysorbate 20, and mannitol, and uses of FX activators (e.g., RVV-X) or compo...
|
|
WO/2023/246487A1 |
Provided is use of Thonningianin A in the preparation of an antifungal drug synergist. When combined with an antifungal drug, Thonningianin A not only can reduce the dosage of the drug, but also ensure the treatment effect on fungal infe...
|
|
WO/2023/246928A1 |
The present invention relates to an improved GLP-1 receptor agonist, a fusion protein containing the improved GLP-1 receptor agonist, a polynucleotide encoding the fusion protein, a vector containing the polynucleotide, a cell, and the u...
|
|
WO/2023/242097A1 |
The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders, inflammatory diseases and/or genetic disorders. The present invention ...
|
|
WO/2023/242104A1 |
The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders inflammatory diseases and/or genetic disorders. The present invention r...
|
|
WO/2023/242235A1 |
The present invention relates to treatment of cancer, in particular to methods for sensitising cancer cells to a NEDD8 inhibitor by administering an effective amount of an ABCG2 inhibitor and a NEDD8 activating enzyme (NAE) inhibitor, su...
|
|
WO/2023/244026A1 |
The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer, the pharmaceutical composition comprising an FOXM1 inhibitor and an immune checkpoint inhibitor as active ingredients. The FO...
|
|
WO/2023/243935A1 |
The present invention relates to a pharmaceutical composition for preventing or treating acne. More specifically, the present invention comprises antibiotics, bentonite, kaolin clay, corn starch, agar, titanium dioxide (TiO2), and talc, ...
|
|
WO/2023/243689A1 |
The present invention provides: a sepsis and/or septic shock therapeutic agent containing, as an active ingredient, a compound that suppresses phosphorylation of threonine at position 749 of human STAT1; a method for screening a candidat...
|
|
WO/2023/240376A1 |
The present invention belongs to the technical field of medicines, and relates to the technical field of genetic engineering, in particular to use of an intestinal epithelial cell nuclear receptor repressor NCoR as a new target for preve...
|
|
WO/2023/243659A1 |
Provided is a pharmaceutical composition for treating obsessive-compulsive disorder. The present invention pertains to: (1) a pharmaceutical composition containing a dopamine D1 receptor stimulant as an active ingredient for treating o...
|
|
WO/2023/196899A9 |
The present invention recognizes that there is a long felt need for methods of treating cancer. A first aspect of the present invention generally relates to methods of screening for treatments of cancer. A second aspect of the present in...
|
|
WO/2023/241799A1 |
Aspects of the invention concern the use of monomeric flavanol- type compounds, such as (+)-catechin, (-)-catechin, (-F)-epicatechin, (-)-epicatechin, (-F)-epicatechin gallate, (-)-epicatechin gallate, (+) -gallocatechin, (-)-gallocatech...
|
